09 April 2019

NICE, 10 Spring Gardens, London SW1A 2BU

Final Agenda 

The meeting will start promptly at 10:00 and is expected to finish at approximately 15:00

Please note that this agenda is subject to change before the meeting.

The Committee for Medicinal Products for Human Use (at the European Medicines Agency) has not yet given its regulatory opinion for cemiplimab for treating cutaneous squamous cell carcinoma and as a consequence this discussion will take place in a part 2 session (part 2 sessions are closed to public observers).

  1. Appraisal of Cemiplimab for treating cutaneous squamous cell carcinoma [ID1367]
    • 1.1. Declarations of interest – Part 2 only (closed session)
    • 1.2. Introduction by the Chair, Dr Jane Adam  Part 2 only (closed session)
    • 1.3. Presentation by the Lead team Dr Roger Whittaker, Dr Rita Faria and Ms Pamela Rees  Part  2 only (closed session)
    • 1.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)

To print an agenda, please right click and select 'Print' from the menu.

Date, time and venue of next meeting

The next meeting will take place on  Thursday 16 May 2019 at 10am,, London venue (tbc)

Please note all timings are approximate.

 

Registration period: 12 to 26 March 2019
Registration is closed.